These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 16981805)

  • 21. Incretin mimetics and dipeptidyl peptidase-4 inhibitors: innovative treatment therapies for type 2 diabetes.
    Davidson JA; Parente EB; Gross JL
    Arq Bras Endocrinol Metabol; 2008 Aug; 52(6):1039-49. PubMed ID: 18820816
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes.
    Green BD; Flatt PR; Bailey CJ
    Diab Vasc Dis Res; 2006 Dec; 3(3):159-65. PubMed ID: 17160910
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus.
    Campbell RK
    Ann Pharmacother; 2007 Jan; 41(1):51-60. PubMed ID: 17190843
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gliptins.
    Grouzmann E; Buclin T; Biollaz J
    Lancet; 2007 Jan; 369(9558):269. PubMed ID: 17258657
    [No Abstract]   [Full Text] [Related]  

  • 25. Distinguishing among incretin-based therapies. Patient education and self-management.
    Campbell RK; Cobble ME; Reid TS; Shomali ME
    J Fam Pract; 2010 Sep; 59(9 Suppl 1):S28-30. PubMed ID: 20824237
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A review of the effects of antihyperglycaemic agents on body weight: the potential of incretin targeted therapies.
    Barnett A; Allsworth J; Jameson K; Mann R
    Curr Med Res Opin; 2007 Jul; 23(7):1493-507. PubMed ID: 17559747
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent advances in incretin-based therapies.
    Russell-Jones D; Gough S
    Clin Endocrinol (Oxf); 2012 Oct; 77(4):489-99. PubMed ID: 22804841
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emerging incretin based therapies for type 2 diabetes: incretin mimetics and DPP-4 inhibitors.
    Stonehouse A; Okerson T; Kendall D; Maggs D
    Curr Diabetes Rev; 2008 May; 4(2):101-9. PubMed ID: 18473757
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sitagliptin: Profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes.
    Gallwitz B
    Drugs Today (Barc); 2007 Jan; 43(1):13-25. PubMed ID: 17315049
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Managing postprandial glucose levels in patients with diabetes.
    Tenzer-Iglesias P; Brunton S
    J Fam Pract; 2008 Jan; 57(1 Suppl Managing):S17-24. PubMed ID: 18662529
    [No Abstract]   [Full Text] [Related]  

  • 31. Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.
    Mikhail N
    Expert Opin Investig Drugs; 2008 Jun; 17(6):845-53. PubMed ID: 18491986
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients.
    Balas B; Baig MR; Watson C; Dunning BE; Ligueros-Saylan M; Wang Y; He YL; Darland C; Holst JJ; Deacon CF; Cusi K; Mari A; Foley JE; DeFronzo RA
    J Clin Endocrinol Metab; 2007 Apr; 92(4):1249-55. PubMed ID: 17244786
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The physiology of incretin hormones and the basis for DPP-4 inhibitors.
    McKennon SA; Campbell RK
    Diabetes Educ; 2007; 33(1):55-6, 60-2, 65-6. PubMed ID: 17272793
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacological management of type 2 diabetes: the potential of incretin-based therapies.
    Charbonnel B; Cariou B
    Diabetes Obes Metab; 2011 Feb; 13(2):99-117. PubMed ID: 21199262
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
    Jellinger PS
    Postgrad Med; 2011 Jan; 123(1):53-65. PubMed ID: 21293084
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Distinguishing among incretin-based therapies. Glucose-lowering effects of incretin-based therapies.
    Campbell RK; Cobble ME; Reid TS; Shomali ME
    J Fam Pract; 2010 Sep; 59(9 Suppl 1):S10-9. PubMed ID: 20824235
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New treatments for diabetes.
    Bloomgarden ZT; Inzucchi SE
    N Engl J Med; 2007 May; 356(21):2219-20; author reply 2222-3. PubMed ID: 17522409
    [No Abstract]   [Full Text] [Related]  

  • 38. Incretin-based therapy of type 2 diabetes mellitus.
    Knop FK; Vilsbøll T; Holst JJ
    Curr Protein Pept Sci; 2009 Feb; 10(1):46-55. PubMed ID: 19275672
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of incretin-based therapies in the management of type 2 diabetes.
    Bandyopadhyay P
    Drug News Perspect; 2009 Nov; 22(9):559-67. PubMed ID: 20072733
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Finding new treatments for diabetes--how many, how fast... how good?
    Nathan DM
    N Engl J Med; 2007 Feb; 356(5):437-40. PubMed ID: 17267901
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.